Recent practice guidelines have recognized the administration of chemotherapy and/or radiation therapy prior to pancreatectomy for localized pancreatic ductal adenocarcinoma (PDAC) as the preferred treatment strategy for patients with borderline resectable cancer1
and an acceptable treatment option for patients with potentially resectable cancer.2
Purported benefits of this approach include the selection of patients with favorable tumor biology and a physiologic profile appropriate for major surgery, early treatment of micrometastatic disease, facilitation of a margin-negative resection, and guaranteed delivery of all components of multimodality therapy.
During the past 3 decades, refinement of the therapeutic regimens administered in the preoperative setting has permitted the rational use of potentially curative surgery in patients with anatomically advanced cancer and has contributed to a significant increase in overall survival duration following pancreatectomy. Read more . . .